Kodiak skyrockets on positive study data for 2 eye drugs — Live Feedhttps://www.live-feeds.com/feed/kodiak-skyrockets-on-positive-study-data-for-2-eye-drugsContinuously updated, source-cited coverage. Kodiak Sciences stock surges on positive Phase 3 wet AMD trial datahttps://www.live-feeds.com/feed/kodiak-skyrockets-on-positive-study-data-for-2-eye-drugshttps://www.live-feeds.com/feed/kodiak-skyrockets-on-positive-study-data-for-2-eye-drugs#u101192Mon, 05 Oct 2026 03:35:58 +0000Kodiak Sciences shares rose between 120% and 178% on September 28 after its Phase 3 DAYBREAK trial met primary endpoints for two eye-disease candidates. Zenkuda (tarcocimab tedromer) and tabirafusp alfa tedromer (KSI-501) demonstrated statistical equivalence to aflibercept, sold as Eylea, in treating treatment-naive patients with wet age-related macular degeneration. Zenkuda achieved an average vision improvement of 7.2 letters compared to 7.6 for Eylea. The company now plans to seek regulatory approval for Zenkuda this year, adding more than $3 billion to its market value.Why it mattersThe re